Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2 Positive Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02659514
What this trial is testing

Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Spectrum Pharmaceuticals, Inc 67
Testing effectiveness (Phase 2)Study completedNCT01068704
What this trial is testing

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Bristol-Myers Squibb 4
Not applicableStudy completedNCT04671615
What this trial is testing

Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

Who this might be right for
Metastatic Breast Cancer
Pfizer 559
Testing effectiveness (Phase 2)Ended earlyNCT00810017
What this trial is testing

Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

Who this might be right for
HER-2 Positive Metastatic Breast Cancer
Medstar Health Research Institute 2
Not applicableStudy completedNCT04850625
What this trial is testing

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine

Who this might be right for
Breast Cancer
Fudan University 224
Early research (Phase 1)Active Not RecruitingNCT04288089
What this trial is testing

H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

Who this might be right for
Receptors, EstrogenGenes, Erbb-2Breast Neoplasms
Eisai Inc. 31
Testing effectiveness (Phase 2)Study completedNCT05963997
What this trial is testing

Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer
Carrick Therapeutics Limited 49
Early research (Phase 1)Study completedNCT01097460
What this trial is testing

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Who this might be right for
Breast Neoplasms
Merrimack Pharmaceuticals 16
Large-scale testing (Phase 3)Ended earlyNCT00508274
What this trial is testing

Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 52
Early research (Phase 1)Study completedNCT05471648
What this trial is testing

A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers

Who this might be right for
Breast Cancer
EirGenix, Inc. 135
Testing effectiveness (Phase 2)Study completedNCT02015559
What this trial is testing

Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerOral Complications+5 more
Jonsson Comprehensive Cancer Center 61
Not applicableApproved For MarketingNCT03133988
What this trial is testing

Margetuximab Expanded Access Program

Who this might be right for
HER2-positive Breast CancerHER2-positive Carcinoma
TerSera Therapeutics LLC
Testing effectiveness (Phase 2)UnknownNCT05205200
What this trial is testing

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

Who this might be right for
Breast CancerMetastatic Cancer
Fudan University 338
Not applicableWithdrawnNCT05244434
What this trial is testing

Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer

Who this might be right for
Advanced Breast AdenocarcinomaAdvanced HER2-Negative Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8+12 more
City of Hope Medical Center
Early research (Phase 1)Ended earlyNCT02384746
What this trial is testing

Phase I Study of the Combination of MLN9708 and Fulvestrant

Who this might be right for
Breast Cancer
Dartmouth-Hitchcock Medical Center 9
Testing effectiveness (Phase 2)Study completedNCT03703466
What this trial is testing

Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company 72
Not applicableStudy completedNCT05034393
What this trial is testing

Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil

Who this might be right for
Breast Cancer
Latin American Cooperative Oncology Group 308
Large-scale testing (Phase 3)Study completedNCT02472964
What this trial is testing

Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.

Who this might be right for
Breast Cancer
Mylan Inc. 500
Early research (Phase 1)Study completedNCT01857193
What this trial is testing

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 132
Testing effectiveness (Phase 2)Active Not RecruitingNCT04576455
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Who this might be right for
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 303
Next Page